

Hiroko Bando

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5918270/publications.pdf>

Version: 2024-02-01

47
papers

605
citations

840119

11
h-index

642321

23
g-index

52
all docs

52
docs citations

52
times ranked

860
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 44-50.	0.7	90
2	Increased Soluble CD155 in the Serum of Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0152982.	1.1	83
3	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3743-3752.	0.8	50
4	A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. <i>Nature Cell Biology</i> , 2022, 24, 565-578.	4.6	42
5	Vascular endothelial growth factor and bevacitumab in breast cancer. <i>Breast Cancer</i> , 2007, 14, 163-173.	1.3	41
6	Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells. <i>Cancer Science</i> , 2017, 108, 362-372.	1.7	39
7	Ex Vivo and In Vivo Assessment of the Non-linearity of Elasticity Properties of Breast Tissues for Quantitative Strain Elastography. <i>Ultrasound in Medicine and Biology</i> , 2014, 40, 1755-1768.	0.7	36
8	A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel+carboplatin+trastuzumab+pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 135-146.	1.1	26
9	High expression of soluble CD155 in estrogen receptor-negative breast cancer. <i>Breast Cancer</i> , 2020, 27, 92-99.	1.3	20
10	FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations. <i>Cancer Science</i> , 2016, 107, 281-289.	1.7	18
11	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462.	0.8	16
12	Neoantigen prediction in human breast cancer using RNA sequencing data. <i>Cancer Science</i> , 2021, 112, 465-475.	1.7	13
13	Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study. <i>Breast Cancer</i> , 2021, 28, 896-903.	1.3	11
14	Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2. <i>International Journal of Clinical Oncology</i> , 2022, 27, 281-300.	1.0	11
15	Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. <i>International Journal of Clinical Oncology</i> , 2022, 27, 265-280.	1.0	11
16	Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase III clinical trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 117-131.	1.1	10
17	Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan. <i>Breast Cancer</i> , 2014, 21, 656-663.	1.3	8
18	Elevated Production of Mitochondrial Reactive Oxygen Species via Hyperthermia Enhanced Cytotoxic Effect of Doxorubicin in Human Breast Cancer Cell Lines MDA-MB-453 and MCF-7. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9522.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Glomus tumor of a female breast: a case report and review of the literature. <i>Journal of Medical Ultrasonics</i> (2001), 2014, 41, 385-388.	0.6	7
20	Enhancement of PDT-cytotoxicity via ROS induced by indomethacin in metastatic breast cancer. <i>Journal of Porphyrins and Phthalocyanines</i> , 2019, 23, 1440-1447.	0.4	7
21	Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). <i>Investigational New Drugs</i> , 2021, 39, 217-225.	1.2	7
22	Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. <i>BMC Medicine</i> , 2022, 20, 136.	2.3	7
23	Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. <i>Breast Cancer</i> , 2019, 26, 535-543.	1.3	5
24	Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). <i>Breast Cancer</i> , 2021, 28, 1023-1037.	1.3	5
25	A case of hemorrhagic cystitis caused by nab-paclitaxel. <i>International Cancer Conference Journal</i> , 2016, 5, 187-191.	0.2	4
26	The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 625-630.	1.1	4
27	Preoperative diagnosis of a giant cell tumor of soft tissue arising from the breast by ultrasound-guided core needle biopsy. <i>Journal of Medical Ultrasonics</i> (2001), 2019, 46, 257-261.	0.6	3
28	Investigation of the significance of population-based breast cancer screening among women aged under 40 years. <i>Breast Cancer</i> , 2021, 28, 75-81.	1.3	3
29	Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry). <i>Journal of Clinical Medicine</i> , 2021, 10, 1370.	1.0	3
30	Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). <i>Cancers</i> , 2021, 13, 4008.	1.7	3
31	Physicians' knowledge, attitudes and practice pattern for breast cancer diagnosed during pregnancy: a survey among breast care specialists in Japan. <i>Breast Cancer</i> , 2020, 27, 796-802.	1.3	2
32	Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. <i>Cancer Medicine</i> , 2020, 9, 9246-9255.	1.3	2
33	Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16). <i>Journal of Clinical Oncology</i> , 2016, 34, 599-599.	0.8	2
34	Echocardiography image quality of global longitudinal strain in cardio-oncology: a prospective real-world investigation. <i>Journal of Echocardiography</i> , 2022, 20, 159-165.	0.4	2
35	2D and 3D Refraction Based X-ray Imaging Suitable for Clinical and Pathological Diagnosis. <i>AIP Conference Proceedings</i> , 2007, , .	0.3	1
36	Physical fitness level in Japanese breast cancer survivors. <i>Japanese Journal of Physical Fitness and Sports Medicine</i> , 2018, 67, 169-176.	0.0	1

#	ARTICLE	IF	CITATIONS
37	Four cases of Trousseau syndrome associated with breast cancer that exhibited central nervous system manifestations. <i>International Cancer Conference Journal</i> , 2020, 9, 146-150.	0.2	1
38	Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1025-1025.	0.8	1
39	Characteristics of Cancers in Adolescents and Young Adults Compared with Those in Adults in Their 60s: A Single-Center Experience. <i>Oncology</i> , 2022, 100, 140-147.	0.9	1
40	Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC). <i>Breast Cancer</i> , 0, , .	1.3	1
41	Extreme response to nab-paclitaxel and trastuzumab treatment in two patients with locally advanced or recurrent breast cancer. <i>International Cancer Conference Journal</i> , 2014, 3, 38-42.	0.2	0
42	Fibroadenoma in axillary ectopic breast tissue: a case report. <i>Choonpa Igaku</i> , 2021, 48, 293-297.	0.0	0
43	Enhancement of PDT-cytotoxicity via ROS induced by indomethacin in metastatic breast cancer. , 2021, , 361-368.		0
44	Preference of end-of-life discussion at diagnosis in patients with advanced/recurrent cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21511-e21511.	0.8	0
45	Features of adolescent and young adult cancer patients in Japan.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13081-e13081.	0.8	0
46	Abstract OT1-18-01: A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2 negative breast cancer: JCOG1919E/AMBITION study. <i>Cancer Research</i> , 2022, 82, OT1-18-01-OT1-18-01.	0.4	0
47	Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (ITOP-B). <i>BMJ Open</i> , 2022, 12, e058755.	0.8	0